Allarity Therapeutics, Inc.

Contributing Author

Recent Articles by Allarity Therapeutics, Inc.

Mar-06	Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization ALLR +21.57% GlobeNewswire
Feb-18	Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need ALLR +8.67% GlobeNewswire
Feb-03	Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment ALLR -8.06% GlobeNewswire
Dec-31	Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders ALLR +6.93% GlobeNewswire
Nov-14	Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates ALLR GlobeNewswire
Sep-22	Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months ALLR +15.58% GlobeNewswire
Sep-17	Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 ALLR GlobeNewswire
Aug-26	Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer ALLR +51.92% GlobeNewswire
Aug-15	Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships ALLR -5.00% ALLR GlobeNewswire
Jul-15	Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP Platform Utilization ALLR GlobeNewswire
Jul-07	Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer ALLR GlobeNewswire
Jun-30	Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP Companion Diagnostic ALLR GlobeNewswire
Jun-27	Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer ALLR GlobeNewswire
Jun-11	Allarity Therapeutics Announces Changes to Board of Directors ALLR -5.31% ALLR GlobeNewswire
Jun-04	Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of Action ALLR GlobeNewswire
Jun-02	Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer ALLR GlobeNewswire
May-12	Allarity Therapeutics Announces Participation in Pharma Partnering Summit US ALLR GlobeNewswire
May-09	Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment ALLR GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)